Table 1.

Summary of clinical presentations, paraclinical investigations and follow-up data of patients with autoimmune encephalopathy.

Case number	Age	Antibody	Clinical presentation	CSF	MRI	EEG	Time to diagnosis (months)	mRS (diagnosis)	mRS (last visit)
1	16	NMDA	Psychosis, seizures, encephalopathy, rigidity, dyskinesias, dysautonomia	Cells-2, Protein-57	Occipital subcortical hyperintensities	Extreme delta brush	4	5	0
2	16	NMDA	Seizures, encephalopathy, dyskinesias, dysautonomia, akinetic mutism	NL	NL	Extreme delta brush	4	5	0
3	17	NMDA	Psychosis, seizures, encephalopathy, myoclonus, dyskinesias, dysautonomia	NL	NL	Slow theta and delta waves	4	5	0
4	26	NMDA	Encephalopathy, dyskinesias, dysautonomia, dystonia	Cells-336, Protein-16	Cortical hyperintensities	Diffuse slowing	2	4	2
5	26	NMDA	Psychosis, myoclonus, encephalopathy, dyskinesias, seizures, dyasutonomia	Cells-22, Protein-20	NL	Diffuse slowing	4	4	0
6	4	NMDA	Seizures, agressiveness, encephalopathy, dyskinesias, akinetic mutism	NL	NL	Slow activity	3	5	4
7	5	NMDA	Encephalopathy, dyskinesias, dystonia	NL	NL	Diffuse slowing	4	4	0
8	14	NMDA	Status epilepticus, Encephalopathy, dyskinesias, dystonia	NL	NL	Status Epilepticus	5	5	6
9	23	NMDA	Psychosis, akinetic mutism, dyskinesias, dysautonomia	Cells−197, Protein-21	NL	Diffuse slowing	3	5	0
10	75	LGI1	Faciobrachial dystonic seizures, encephalopathy, memory loss, hyponatremia	Cells−10, Protein-40	Right basal nuclei and hipocampal	Diffuse slowing	6	5	3
11	73	LGI1	Faciobrachial dystonic seizures, encephalopathy, memory loss, hyponatremia	NL	NL	Diffuse slowing	9	4	0
12	67	AMPA	Hyponatremia, agitation, insomnia, memory loss	NL	NL	Diffuse slowing	3	4	3
13	17	NMDA	Seizures, agressiveness, mutism, memory loss, encephalopathy	Cells-16, Protein-29	NL	Diffuse slowing	5	5	1

NMDA, N-methyl-D-asparthate; LGI1, Leucine-rich-glioma-inactivated-1; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NL, Normal; CSF, Cerebrospinal fluid; MRI, Magnetic resonance image; mRS, modified Rankin Scale.